Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Interventions for HIV Remission in People on ART
NCT07903441Phase 2Recruiting
- Sponsor
- Federal University of São Paulo
- Start
- Aug 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial of nicotinamide riboside, nicotinamide, leronlimab, maraviroc, dolutegravir and 2 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Federal University of São Paulo. Primary endpoints: Evolution of viral load of HIV RNA, Evolution of cell-associated HIV RNA in PBMCs and 4 more. Started Aug 2026; status: recruiting.
02
Drugs
nicotinamide ribosidenicotinamideleronlimabmaravirocdolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07903441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903441.